CVS Health increases profit scope for 2021 and vision is supported for 2022
CVS Health Corp. CVS, up 1.23% Tuesday, said it expects earnings of $5.87 to $5.92 per share in 2021, down from its previous forecast of $5.50 to $5.61. The company now expects full-year 2021 adjusted earnings of $8.33 to $8.38 per share, up from its previous view of earnings of at least $8 per share. Wall Street analysts had expected earnings of $8.04 per share for 2021, according to a FactSet survey. CVS Health continues to forecast 2022 earnings of $7.04 to $7.24 per share and adjusts 2022 earnings of $8.10 to $8.30. Analysts target 2022 earnings of $8.26 per share. Members of CVS Health's leadership team will present these performance targets in a webcast at 8:15 a. m. EDT. CVS Health shares rose 40.3% over the past year, compared with a 22.9% gain for the S&P 500.
SOURCE
Gelsi, S. (2022, January 11). CVS Health hikes 2021 earnings range and backs 2022 view. MarketWatch. Retrieved January 11, 2022, from https://www.marketwatch.com/story/cvs-health-hikes-2021-earnings-range-and-backs-2022-view-2022-01-11?siteid=yhoof2
Bay Street Capital Holdings is a subsidiary of Maridea Global Capital Management. Maridea refers to Maridea Global Capital Management and all of its subsidiaries and affiliates. Maridea Wealth Management LLC, a subsidiary, is a registered investment advisor and may also conduct business under the names of Huckleberry Capital Management and/or Bay Street Capital Holdings.
Maridea Wealth Management LLC provides investment advisory and related services for clients nationally. Gagni Wealth Management LLC, also a subsidiary, is a registered investment advisor providing investment advisory and related services to clients nationally. Maridea will maintain all applicable registration and licenses as required by the various states in which Maridea conducts business, as applicable. Maridea Wealth Management LLC is an SEC registered investment advisor and Gagni Wealth Management LLC is a Texas state registered investment advisor. For additional information, please click here for our disclosures page.